- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Mediators of Inflammation
Volume 2015 (2015), Article ID 484357, 10 pages
Cardiac-Restricted IGF-1Ea Overexpression Reduces the Early Accumulation of Inflammatory Myeloid Cells and Mediates Expression of Extracellular Matrix Remodelling Genes after Myocardial Infarction
1National Heart and Lung Institute, Imperial College London, London, UK
2Australian Regenerative Medicine Institute, EMBL Australia, Monash University, Clayton, Melbourne, VIC, Australia
3The Jackson Laboratory, Bar Harbor, ME, USA
Received 23 July 2015; Accepted 13 September 2015
Academic Editor: Michael Schnoor
Copyright © 2015 Enrique Gallego-Colon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Strategies to limit damage and improve repair after myocardial infarct remain a major therapeutic goal in cardiology. Our previous studies have shown that constitutive expression of a locally acting insulin-like growth factor-1 Ea (IGF-1Ea) propeptide promotes functional restoration after cardiac injury associated with decreased scar formation. In the current study, we investigated the underlying molecular and cellular mechanisms behind the enhanced functional recovery. We observed improved cardiac function in mice overexpressing cardiac-specific IGF-1Ea as early as day 7 after myocardial infarction. Analysis of gene transcription revealed that supplemental IGF-1Ea regulated expression of key metalloproteinases (MMP-2 and MMP-9), their inhibitors (TIMP-1 and TIMP-2), and collagen types (Col 1α1 and Col 1α3) in the first week after injury. Infiltration of inflammatory cells, which direct the remodelling process, was also altered; in particular there was a notable reduction in inflammatory Ly6C+ monocytes at day 3 and an increase in anti-inflammatory CD206+ macrophages at day 7. Taken together, these results indicate that the IGF-1Ea transgene shifts the balance of innate immune cell populations early after infarction, favouring a reduction in inflammatory myeloid cells. This correlates with reduced extracellular matrix remodelling and changes in collagen composition that may confer enhanced scar elasticity and improved cardiac function.
Cardiovascular diseases (CVD) are the major cause of death globally, with myocardial infarction (MI) being one of the main causes of mortality . After MI, the damaged myocardium releases inflammatory signals that trigger a cascade of cellular processes in order to repair damaged tissue, leading to the formation of scar tissue and left ventricular (LV) dysfunction [2, 3].
Our laboratory has characterised the therapeutic properties of the insulin-like growth factor-1 Ea (IGF-1Ea) propeptide during wound healing/regeneration and pathological inflammation. The IGF-1 gene is encoded in 70 kb of genomic DNA distributed over six exons and five introns [4, 5]. Use of alternative start codons generates proteins with N-terminal variability while different exon use at the 3′ end generates multiple C-terminal extension-peptides, termed E-peptides. The most predominant is a 35-amino-acid-long E-peptide, termed Ea, alternating with a far less abundant E-peptide termed Eb or mechanogrowth factor (MGF) [6, 7]. The E-peptides control local IGF-1 bioavailability by adhering strongly to the extracellular matrix (ECM), retaining the propeptides locally and preventing their release into the circulation . Expressed as a cardiomyocyte-specific transgene or delivered locally to the mouse heart, IGF-1Ea improves functional recovery after cardiac injury [9, 10]; however the underlying mechanisms are not fully understood.
Tissue restructuring after infarction involves the breakdown of the ECM by proteolytic enzymes, mainly the matrix metalloproteinases (MMP) MMP-2 and MMP-9, balanced by interaction with tissue inhibitors of metalloproteinases (TIMPs) . Initially a temporary matrix is formed, primarily composed of collagen type III (Col Iα3), providing a scaffold for replacement cells and structural integrity to the heart, thereby reducing the risk of LV dilation and rupture [12, 13]. This is later replaced by collagen type I (Col Iα1) which will constitute the permanent ECM . Col Iα1 confers tensile strength and resistance to stretch and deformation, while Col Iα3 confers compliance. Their balance determines cardiac tissue stiffness with increased Col Iα3 to Col Iα1 ratio generating a more resilient left ventricle [13, 14].
Innate immune cells recruited to the injured myocardium from the blood include neutrophils, monocytes, macrophages, and dendritic cells [15–17]. They play a prominent role in remodelling, producing the MMPs that break down the matrix, synthesising new ECM components, and activating fibroblasts to myofibroblasts which will later in the inflammatory process be the main producers of matrix proteins . The tissue microenvironment at a given time after MI influences the recruitment of immune cells as well as their phenotypic and functional properties. This is especially relevant for the macrophage population which undergoes a time-dependent shift between inflammatory and reparative functions [3, 18]. At early time points after injury, the majority of macrophages produce inflammatory cytokines and reactive oxygen species including interleukin- (IL-) 1β, IL-12, MMP-9, and nitric oxide. These are termed inflammatory or M1-polarised macrophages, which express high levels of Ly6C and function to recruit more inflammatory cells and phagocytose cellular debris and produce growth factors . As the inflammation progresses, reparative macrophages accumulate in the infarct area. In contrast to the inflammatory macrophages, these cells, many of which express CD206, are involved in the suppression of inflammation due to high production of IL-10 and TGF-β [3, 19] and assist in the progression from inflammation to repair.
They also perform reparative roles promoting cell growth, angiogenesis, and remodelling of the ECM. Additionally, different monocyte populations can be distinguished by Ly6C in the mouse and may preferentially give rise to inflammatory versus reparative macrophages.
We have previously shown that IGF-1Ea and its mature circulating form IGF-1 can modulate immune responses and suppress pathological inflammation by inducing regulatory cytokines and immune cell types [20, 21]. In the heart, IGF-1Ea increased expression of IL-10 after cardiotoxin injury and decreased levels of IL-1β suggesting that a shift in immune cell populations may also occur in the heart . In the present study, we investigated whether there was a difference in the immune cell dynamics after MI in transgenic IGF-1Ea hearts and whether this had a carry-on effect on tissue remodelling.
2. Materials and Methods
2.1. Cardiac Injury Model
Myocardial infarction by permanent left coronary artery occlusion was induced in wild-type (WT) and αMHC.IGF-1Ea male mice which were 8 to 12 weeks old. Surgeries were performed under mechanical ventilation with 1–2.5% isofluorane. The chest cavity was opened through the left fourth intercostal space. The heart was exposed and the left coronary artery was ligated using an 8.0 mm non-absorbable suture (Ethicon-Johnson & Johnson, USA) below the left atrium to produce an ischemic region of 20–30% of the left ventricle area. The chest cavity and skin were sutured with 6.0 mm silk sutures (Ethicon-Johnson & Johnson, USA). Analgesic treatment with buprenorphine (0.3 mg/kg, s.c.) was provided before and after surgery. They were housed in individually ventilated cages in temperature-controlled facilities on a 12-hour light/dark cycle on standard diet. All mouse procedures were approved by the Imperial College London Ethical Committee and were in accordance with national and international regulations (UK Home Office Project license 70/7589).
Echocardiographic measurements were taken using a high-frequency ultrasound system Vevo 770 (VisualSonics, Inc., Canada) with a 30 MHz linear transducer and recorded images were analyzed by using the Vevo 770 workstation software. Mice were anesthetised with 1-2% isofluorane, and the anesthetic flow rate was adjusted to maintain heart rate of approximately beats per minute. Furthermore, warmed ultrasound gel and a heating platform were used to maintain body temperature at °C to minimise variation between mice. This analysis was performed at basal level, 1, 3, 4, 7, and 28 days after MI to evaluate left ventricle cardiac function, chamber dimensions, and infarct size.
2.3. Masson’s Trichrome Staining
Samples were fixed in paraformaldehyde (4% in PBS) for 48 h, washed in PBS, dehydrated, and embedded in paraffin wax. Five-micron-thick sections were stained with Celestine Blue for 5 minutes, washed in tap water, and then incubated in haematoxylin for 5 minutes. Slides were then incubated with Acid Fuchsin for 5 minutes, rinsed in distilled water, incubated in phosphomolybdic acid (1%), and then rinsed in distilled water before staining with Methyl Blue for 2-3 minutes. Slides were dehydrated in ascending concentrations of ethanol, cleared in xylene, and mounted in DPX (VWR, UK).
2.4. Cell Isolation
To analyse neutrophils, monocytes, macrophages, and dendritic cells, a single cell suspension was prepared from hearts before or at various time points after MI (days 1, 3, 5, 7, and 28 after operation). The hearts were mechanically dissociated using surgical scissors and subsequently treated with a 1x Hank’s Balanced Salt Solution (HBSS) (Invitrogen, USA), enzymatic dissociation buffer containing 0.1 mg/mL Liberase TH Research Grade (Roche Diagnostics, UK), 50 μg/mL of DNaseI (Roche Diagnostics, UK), 10 mM HEPES (Invitrogen, USA), and 30 mM Taurine (Sigma, UK) for 4 cycles of 10 min at 37°C. After each 10 min incubation cycle, the cells were collected and filtered using a 70 μm cell strainer (BD Pharmingen, USA) and an equal volume of ice cold 1x HBSS containing 10 mM HEPES, 30 mM Taurine (Sigma, UK), and 20% Fetal Bovine Serum (FBS) (GE Healthcare, USA) was added to the enzyme dissociation buffer. The cells were pelleted at 320 g for 7 min at 4°C and washed with the 1x HBSS media solution containing 20% FBS as described above. Under these isolation conditions, adult cardiomyocytes are predominately lysed, as the enzymatic dissociation buffer is toxic to these large, fragile cells . An aliquot of the cell suspension was used to quantify the cell concentration/mL using a Beckman Coulter Vi-Cell XR cell counter (Beckman Coulter, High Wycombe, UK).
2.5. Flow Cytometry and Cell Sorting
Isolated cells were incubated in a 1x Dulbecco’s Modified Eagle Medium (DMEM) solution (Gibco, Life Technologies, UK) containing 2% FBS and 10 mM HEPES for 30 min, on ice, in the dark, with the following primary antibodies: CD11b-PE (BD Biosciences; catalogue 553311), F4-80-Biotin (eBioscience; catalogue 13-4801-85), CD45-APC-Cy7 (BioLegend; catalogue 103116), CD206-PerCP-Cy5.5 (BioLegend; catalogue 141716), Ly6C-APC (eBioscience; catalogue 17-5932-82), and Ly6G-AlexaFluor700 (BioLegend; catalogue 127622). Samples stained with biotin-labelled primary antibody were incubated with a streptavidin-PE-Cy7 (eBioscience; catalogue 25-4317-82) secondary antibody for 30 min, on ice, in the dark, with the 1x DMEM media solution as mentioned above. The samples were washed and resuspended in fresh 1x DMEM media solution with 1.5 μM Sytox Blue (Invitrogen. USA) dead cell stain and refiltered using 5 mL, 35 μm filter cap tubes (BD Falcon) just prior to sample acquisition. Flow cytometric cell sorting was performed using a BD FACSAriaI cell sorter (BD Biosciences, Oxford, UK) equipped with a 355 nm UV laser, a 405 nm Violet laser, a 488 nm Blue laser, a 561 nm Yellow-Green laser, and a 640 nm Red laser. The antibody cocktail fluorescence minus one (FMO) controls were used as gating controls for analyses to distinguish positive from negative fluorescence signal (see Supplementary 4–6 in Supplementary Material available online at http://dx.doi.org/10.1155/2015/484357). Total leukocytes (CD45+), neutrophils (CD45+, CD11b+, F4/80−, CD11c−, and Ly6G+), and monocytes (CD45+, CD11b+, CD11c−, Ly6G−, and F4/80−) were analysed. Monocytes were further classified as and monocytes. Macrophages were defined as CD45+, CD11b+, CD11c−, Ly6G−, and F4/80+ and further characterised on the basis of Ly6C and CD206 expression (i.e., / (inflammatory macrophages) and / (reparative macrophages)). Dendritic cells were defined as CD45+, CD11b+, F4/80−, CD11c+, and Ly6G−. Flow Jo software (version 9. 8.5) (Tree Star, Ashland, OR) was used for analysis.
2.6. RNA Isolation and cDNA Generation
Mouse heart tissue was harvested and flushed with cold PBS. Samples from the infarct and remote (non-infarct) myocardium were placed in a 1.5 mL tube and homogenised in TRIzol (Invitrogen, USA) reagent using a rotor-stator homogeniser (Polytron PT 2500 E). Total RNA was isolated according to the TRIzol manufacturer’s instructions. RNA was pelleted, air-dried, and resuspended in DNase/RNase free water and the yield quantified using Nanodrop (Thermo Scientific, USA) at 260 nm. One microgram of RNA was reverse-transcribed into cDNA using the Quantitect Reverse Transcription Kit (QIAGEN, Crawley, UK).
2.7. Quantitative Real-Time PCR
Following cDNA synthesis, quantitative RT-PCR using TaqMan probes (Invitrogen. USA) was performed on an ABI 7900HT Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). The probes used were IGF-1Ea (Mm00710307_m1), IL-10 (Mm00439614_m1), IL-1β (Mm00434228_m1), CCL2 (Mm00441242_m1), CCL5 (Mm01302427_m1), TGFβ (Mm03024053_m1), collagen Iα1 (Mm00801666_g1), collagen Iα3 (Mm01254476_m1), Lox (Mm00495386_m1), MMP2 (Mm00439498_m1), MMP9 (Mm00442991_m1), TIMP1 (Mm00441818_m1), TIMP2 (Mm004418225_m1), actin, alpha 1, skeletal muscle, ACTA, (Mm00808218_g1), Atrial Natriuretic Peptide, and ANP (Mm01255747_g1). Gene expression was determined as fold induction over uninjured hearts after normalising to the reference gene, GAPDH.
Data are presented as mean SEM. Two-tailed Student’s t-test was performed to compare WT and αMHC.IGF-1Ea mice at selected time points after MI. Data were analysed with GraphPad-Prism 5.0 (Graphpad Software, Inc., www.graphpad.com), and differences were considered statistically significant at .
3.1. IGF-1Ea Improves Cardiac Function after Myocardial Infarction
Endogenous IGF-1Ea expression in WT hearts was measured 1, 3, 5, 7, and 28 days after MI in both ischemic and remote (nonischemic) regions. IGF-1Ea levels increased in both the ischemic and remote regions (Figure 1(a)) with a substantially stronger induction in the ischemic area (8-fold over uninjured levels). These results indicate that, similar to other organs, endogenous IGF1-Ea expression is upregulated after cardiac tissue damage [23, 24]. In αMHC.IGF-1Ea hearts, the baseline expression of transgenic IGF-1Ea was much higher than the expression of endogenous IGF-1Ea in WT hearts (average 286-fold) at all experimental time points (Supplementary and 1B). Although far exceeding the expression of endogenous IGF-1Ea, the αMHC.IGF-1Ea transgenic mice provide a suitable model of IGF-1Ea at supraphysiological concentrations of possible therapeutic relevance.
Previously our group showed an improvement in cardiac function in αMHC.IGF-1Ea compared to WT mice one month after MI . To pinpoint the start of functional improvement we extended this analysis and performed echocardiography before and 1, 3, 5, 7, and 28 days after MI (Supplementary Table ). One day following MI, both groups displayed a reduction in ejection fraction (EF); however, αMHC.IGF-1Ea hearts showed significant improvement in left ventricular EF by day 7 after MI (Figure 1(b) and Supplementary Table ). Left ventricular end systolic/diastolic volumes significantly increased after MI in WT hearts, indicating left ventricular dilation, while the αMHC.IGF-1Ea hearts did not display any such signs (Figure 1(c) and Supplementary Table ). In support of the functional data, the expression of molecular markers for cardiac damage such as actin-alpha 1 skeletal muscle (ACTA) and atrial natriuretic peptide (ANP) was significantly reduced in αMHC.IGF-1Ea compared to WT mice 28 days after MI (Figures 1(d) and 1(e)). The peak of endogenous IGF-1Ea in the ischemic region of WT mice by day 7, along with the improvement in cardiac function in αMHC.IGF-1Ea as early as day 7, indicates that IGF-1Ea signalling at early time points is key for cardiac repair.
3.2. Altered Tissue Remodelling in αMHC.IGF-1Ea after Injury
Three days after MI, WT and αMHC.IGF-1Ea hearts displayed infarcts of equal size, quantified by Masson’s trichrome staining (Figure 2(a)). However, by 28 days after infarction, αMHC.IGF-1Ea hearts exhibited smaller scar areas compared to WT (Figures 2(b), 2(c) and 2(d)), as previously reported . This was observed as a reduction in scar length but increased scar thickness, consistent with reduced infarct expansion. As a molecular measurement of fibrosis, we quantified TGF-β mRNA levels which were significantly lower in αMHC.IGF-1Ea than in WT mice after MI (Figure 2(e)). We therefore measured expression of genes involved in ECM turnover and synthesis, MMP-2, MMP-9, TIMP-1, TIMP-2, Col Iα1, Col Iα3, and lysyl oxidase (Lox) at 1, 3, 5, 7, and 28 days after MI. In WT hearts, MMP-9 was upregulated 3 days after MI, followed by MMP-2 at day 7 (Figures 2(f) and 2(g)). Interestingly, neither MMP-2 nor MMP-9 was significantly upregulated in αMHC.IGF-1Ea hearts at any time point. Inhibitors of matrix degradation, TIMP-1 and TIMP-2, had similar expression in WT and αMHC.IGF-1Ea hearts at all time points except for day 7 when TIMP-2 was significantly upregulated in αMHC.IGF-1Ea hearts compared to WT (Figures 2(h) and 2(i)). Taken together, this supports the idea of a net overall reduction in matrix breakdown, which may contribute to the reduced fibrosis observed in αMHC.IGF-1Ea hearts.
We next analysed the composition of the newly synthesised matrix by measuring mRNA expression of the most abundant cardiac ECM collagen, Col Iα1 and Col Iα3, as well as the collagen cross-linker, lox, which increases matrix stiffness. Upregulation of both collagen types was detected by day 3, peaking at day 7 (Figures 2(j) and 2(k)). At this time point, WT hearts expressed significantly more of both collagen types than αMHC.IGF-1Ea hearts. We also noted a difference in the ratio of the two collagen types; αMHC.IGF-1Ea hearts had a reduced Col Iα1/Col Iα3 ratio compared to WT, which was significant at days 3, 7, and 28 (Figure 2(l)). At the peak of collagen upregulation, lox was also upregulated in WT hearts, yet this was not observed in αMHC.IGF-1Ea hearts (Figure 2(m)). These results indicate that IGF-1Ea overexpression reduces ECM turnover after MI and alters the composition of the matrix, with preferential expression of Col Iα3 over Col Iα1 and less cross-linking, which likely alters the mechanical properties of the fibrotic area.
3.3. Distinct Chemokine and Cytokine Production in αMHC-IGF-1Ea Hearts after Myocardial Infarct
Tissue remodelling after injury is closely tied to the inflammatory process. We therefore compared the inflammatory status of the αMHC.IGF-1Ea and WT hearts, monitoring the production of key immune genes IL-1β, IL-10, MCP-1, and CCL5. Expression of the inflammatory cytokine IL-1β was rapidly induced upon injury in WT hearts (66-fold over uninjured) yet was not upregulated as strongly in αMHC.IGF-1Ea hearts (19-fold over uninjured; Figure 3(a)). Similarly the strong upregulation of MCP-1 in WT hearts was not observed in αMHC.IGF-1Ea hearts (Figure 3(b)). IL-10 was also rapidly upregulated, peaking 1 day after MI. In contrast to IL-1β and MCP-1, this immunosuppressive cytokine was upregulated 3-fold higher in αMHC.IGF-1Ea hearts compared to WT controls. Although a second peak of IL-10 mRNA at 7 days was comparable in both WT and αMHC.IGF-1Ea hearts 7 days after MI (Figure 3(c)). CCL5, which is involved in the recruitment of monocytes [26, 27], was upregulated in αMHC.IGF-1Ea hearts 7 days after MI (Figure 3(d)). These data suggest an early bias towards a less inflammatory environment potentially modulating the recruitment of monocytes in αMHC.IGF-1Ea hearts after myocardial infraction.
3.4. IGF-1Ea Modulates Myeloid Cell Recruitment after Myocardial Infarction
To document accumulation of the main innate immune cell populations involved in cardiac inflammation after infarct, single cell suspensions were prepared from whole mouse hearts and analysed by flow cytometry. All cell populations described in this work were identified using the gating strategy shown in Supplementary Figures 3–6.
In WT and αMHC.IGF-1Ea hearts, the total number of infiltrating leukocytes (CD45+) gradually increased after MI, both reaching comparable peak numbers at day 5 (Figure 4(a)). However at the earlier 3-day time point, αMHC.IGF-1Ea hearts contained 49% less leukocytes per milligram of tissue than WT hearts. In examining specific immune cell populations, this difference was partly explained by a 75% reduction in neutrophils (CD45+, CD11b+, F4/80−, CD11c−, and Ly6G+; 186 versus 46 cells/mg of tissue, Figure 4(b)) and a 67% reduction in monocytes (CD45+, CD11b+, CD11c−, Ly6G−, and F4/80−; 191 versus 62 cells/mg of heart, Figure 4(c)); however it was mostly due to reduced presence of macrophages (CD45+, CD11b+, CD11c−, Ly6G−, and F4/80+; 58%, 2276 versus 949 cells/mg of heart, Figure 4(f)). These data agree with the reduced MCP-1 expression observed in αMHC.IGF-1Ea hearts (Figure 3(b)), as it is the principal chemokine involved in monocyte recruitment [26, 28].
The Ly6C surface marker distinguishes two different subsets of monocytes [2, 3]. Analysis of the (CD45+, CD11b+, CD11c−, Ly6G−, F4/80−, and ) and (CD45+, CD11b+, CD11c−, Ly6G−, F4/80−, and ) populations revealed that the reduction of total monocyte numbers at day 3 was attributable to a 20% decrease of the population (102 versus 32 cells/mg of heart), whereas the population was not significantly different in WT compared to αMHC.IGF-1Ea (Figures 4(d) and 4(e)) hearts.
To differentiate between inflammatory and reparative macrophage populations, we used the markers Ly6C and CD206. For this work, only cells that were either Ly6C+/CD206− or Ly6C−/CD206+ were analysed, although we noted a double positive cell population (i.e., CD206+, Ly6C+). However no changes were observed over time between WT and αMHC.IGF-1Ea for the double positive population (Supplementary 2). Both Ly6C+ inflammatory macrophage (CD45+, CD11b+, CD11c−, Ly6G−, F4/80+, and Ly6C+/CD206−) and CD206+ reparative macrophage (CD45+, CD11b+, CD11c−, Ly6G−, F4/80+, and Ly6C−/CD206+) normalised cell numbers were reduced by 71% and 48%, respectively, in αMHC.IGF-1Ea hearts at the day 3 time point (522 versus 153 and 596 versus 310 cells/mg of tissue of heart, resp.; Figures 4(g) and 4(h)); however this was significant only for the Ly6C+ population. By day 7 after MI, macrophage dynamics changed and we observed a greater number of total macrophages in αMHC.IGF-1Ea hearts compared to WT, which was mainly due to a 155% preferential increase in the CD206+ population (575 versus 1468 cells/mg heart, Figure 4(h)). Dendritic cells (CD45+, CD11b+, F4/80−, CD11c+, and Ly6G−) were increased by 48% in αMHC.IGF-1Ea hearts compared to WT 5 days after MI (168 versus 248 cells/mg heart; Figure 4(i)).
In summary, cardiac-restricted expression of an IGF-1Ea transgene limited the early accumulation of innate immune cells at day 3 after MI, with a bias towards the reduction of inflammatory myeloid populations rather than regenerative populations. This reduction corresponds with the lower expression of myeloid chemokines and the less inflammatory milieu observed in the αMHC.IGF-1Ea hearts.
Previous work in our lab showed that local expression of IGF-1Ea promoted functional restoration after MI and observed reduced infarct expansion, thinning, and dilation of the left ventricular wall . We now demonstrate transcriptional modulation of key ECM remodelling genes in the IGF-1Ea hearts associated with tempering of the inflammatory myeloid cell response.
Increased MMP expression after injury has been implicated in contributing to scar destabilisation, as transgenic animal model knockouts of either MMP-2 or MMP-9 have been shown to attenuate LV dilation, rupture, and impairment of cardiac function [29, 30]. While MMP-2 and MMP-9 mRNA expression levels were upregulated in injured WT hearts, this increase was not observed in αMHC.IGF-1Ea hearts. In line with reduced matrix breakdown, mRNA expression of the MMP inhibitor, TIMP-2, was significantly increased in αMHC.IGF-1Ea hearts at day 7 after MI. Thus IGF-1Ea may prevent adverse cardiac remodelling, in part, by modulating transcription of MMPs/TIMPs.
The production of new matrix components was also altered by the presence of the IGF-1Ea transgene with an overall reduction in collagen synthesis, confirmed in histological stains, and a bias towards expression of Col Iα3 over Col Iα1. In MI patients, turnover of cardiac extracellular matrix can be assessed by using circulating collagen peptides as blood biomarkers  and high type I collagen is associated with adverse clinical outcome . A prospective multicentre study further showed that a low type III/type I collagen ratio especially at 1 month after MI is predictive of detrimental left ventricular remodelling as well as cardiovascular deaths and hospitalisation cases for heart failure . Changes in collagen ratios are known to affect the strength and tensile properties of the ECM. It would be interesting to determine whether these properties are modified in the αMHC.IGF-1Ea hearts.
IGF-1Ea could promote the changes in collagen deposition by directly acting on fibroblasts as it promotes both their proliferation and activation to myofibroblasts [34, 35]. Alternatively, IGF-1Ea may influence accumulation and activation of immune cells present at the infarct which in turn regulate myofibroblast activation. Indeed, we observed modulation of the inflammatory process in αMHC.IGF-1Ea hearts, with less monocyte () infiltration into the injured myocardium. This effect is associated with reduced expression of the monocyte chemoattractant MCP-1, although no significant changes were observed in the monocyte population in infarcted hearts, possibly due to CCL5 upregulation.
It is interesting that while complete depletion of monocytes at any stage of repair leads to poor recovery , a more subtle modulation of the monocyte population in the αMHC.IGF-1Ea hearts is associated with improved heart function. Studies abrogating monocyte recruitment using a selective CCR2 inhibitor have resulted in reduced IL-1β, IL-6, MCP-1, and TNFα levels . IGF-1Ea influences macrophage polarisation in skeletal muscle  and we similarly found reduced monocyte and Ly6C+ macrophage normalised cell numbers while CD206+ macrophage numbers were increased by day 7, suggesting that IGF-1Ea promoted a quick progression to the reparative phase of repair by modulating macrophage phenotype. In the αMHC.IGF-1Ea hearts we observed a decrease in MCP-1, which is the chemokine for CCR2, recently shown to distinguish infiltrating monocytes from the resident macrophage population which has a different embryological origin and expresses CD206 [39–41]. It is therefore possible that, in our αMHC.IGF-1Ea transgenic mouse model, IGF-1Ea reduces the infiltration of inflammatory monocytes by preventing upregulation of MCP-1 while still allowing for expansion of the resident macrophage population.
In summary, we show that the αMHC.IGF-1Ea mouse model can modulate several associated aspects of the cellular repair process after MI, including immune cell recruitment, cytokine expression, and matrix turnover. All of these changes occur within the first 7 days after infarct, at which time a functional improvement can already be measured in αMHC.IGF-1Ea hearts compared to WT controls. These data provide new insights into the mechanism of IGF-1Ea and suggest that early immunomodulation is key to successful cardiac repair after injury.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
Robert D. Sampson and Susanne Sattler contributed equally to this work.
The authors are grateful to members of the Rosenthal Laboratory for advice and critique. This work was supported by grants from the European Union’s Seventh Framework Programme Marie Curie Initial Training Network-CardioNeT GA-289600 and British Heart Foundation Grant RM/13/1/30157 to Nadia Rosenthal. Robert D. Sampson and Michael D. Schneider are supported by the British Heart Foundation Centre of Research Excellence and British Heart Foundation Simon Marks Chair. We gratefully acknowledge the support from the British Spanish Society (BSS) for the British Spanish Society/Santander Universities 2015 scholarship that partially supported this project.
- A. S. Go, D. Mozaffarian, V. L. Roger, et al., “Heart disease and stroke statistics—2014 update: a report from the American heart association,” Circulation, vol. 129, pp. e28–e292, 2014.
- N. G. Frangogiannis, “Regulation of the inflammatory response in cardiac repair,” Circulation Research, vol. 110, no. 1, pp. 159–173, 2012.
- N. G. Frangogiannis, “The inflammatory response in myocardial injury, repair, and remodelling,” Nature Reviews Cardiology, vol. 11, no. 5, pp. 255–265, 2014.
- T. Shavlakadze, N. Winn, N. Rosenthal, and M. D. Grounds, “Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle,” Growth Hormone and IGF Research, vol. 15, no. 1, pp. 4–18, 2005.
- P. Rotwein, K. M. Pollock, D. K. Didier, and G. G. Krivi, “Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides,” Journal of Biological Chemistry, vol. 261, no. 11, pp. 4828–4832, 1986.
- J. G. Simmons, J. J. Van Wyk, E. C. Hoyt, and P. K. Lund, “Multiple transcription start sites in the rat insulin-like growth factor-I gene Give rise to IGF-I mRNAs that encode different IGF-I precursors and are processed differently in vitvo,” Growth Factors, vol. 9, no. 3, pp. 205–221, 1993.
- G. I. Bell, M. M. Stempien, N. M. Fong, and L. B. Rall, “Sequences of liver cDNAs encoding two different mouse insulin-like growth factor I precursors,” Nucleic Acids Research, vol. 14, no. 20, pp. 7873–7882, 1986.
- M. S. Hede, E. Salimova, A. Piszczek et al., “E-peptides control bioavailability of IGF-1,” PLoS ONE, vol. 7, no. 12, Article ID e51152, 2012.
- M. P. Santini, L. Tsao, L. Monassier et al., “Enhancing repair of the mammalian heart,” Circulation Research, vol. 100, no. 12, pp. 1732–1740, 2007.
- M. Vinciguerra, M. P. Santini, W. C. Claycomb, A. G. Ladurner, and N. Rosenthal, “Local IGF-1 isoform protects cardiomyocytes from hypertrophic and oxidative stresses via SirT1 activity,” Aging, vol. 2, no. 1, pp. 43–62, 2010.
- D. Vanhoutte, M. Schellings, Y. Pinto, and S. Heymans, “Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window,” Cardiovascular Research, vol. 69, no. 3, pp. 604–613, 2006.
- J. B. Caulfield and T. K. Borg, “The collagen network of the heart,” Laboratory Investigation, vol. 40, no. 3, pp. 364–372, 1979.
- B. I. Jugdutt, “Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways,” Current Drug Targets—Cardiovascular & Haematological Disorders, vol. 3, no. 1, pp. 1–30, 2003.
- B. I. Jugdutt, “Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?” Circulation, vol. 108, no. 11, pp. 1395–1403, 2003.
- M. Nahrendorf and F. K. Swirski, “Monocyte and macrophage heterogeneity in the heart,” Circulation Research, vol. 112, no. 12, pp. 1624–1633, 2013.
- F. Leuschner, P. J. Rauch, T. Ueno et al., “Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis,” The Journal of Experimental Medicine, vol. 209, no. 1, pp. 123–137, 2012.
- X. Yan, A. Anzai, Y. Katsumata et al., “Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction,” Journal of Molecular and Cellular Cardiology, vol. 62, pp. 24–35, 2013.
- S. Frantz and M. Nahrendorf, “Cardiac macrophages and their role in ischemic heart disease,” Cardiovascular Research, vol. 102, no. 2, pp. 240–248, 2014.
- Q. Cao, Y. Wang, D. Zheng et al., “IL-10/TGF-β-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis,” Journal of the American Society of Nephrology, vol. 21, no. 6, pp. 933–942, 2010.
- B. Johannesson, S. Sattler, E. Semenova et al., “Insulin-like growth factor-1 induces regulatory T cell-mediated suppression of allergic contact dermatitis in mice,” Disease Models & Mechanisms, vol. 7, no. 8, pp. 977–985, 2014.
- D. Bilbao, L. Luciani, B. Johannesson, A. Piszczek, and N. Rosenthal, “Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease,” EMBO Molecular Medicine, vol. 6, no. 11, pp. 1423–1435, 2005.
- H. Oh, S. B. Bradfute, T. D. Gallardo et al., “Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12313–12318, 2003.
- A. Philippou, E. Papageorgiou, G. Bogdanis et al., “Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro,” In Vivo, vol. 23, no. 4, pp. 567–576, 2009.
- S. Sanz, J. B. Pucilowska, S. Liu et al., “Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury,” Gut, vol. 54, no. 1, pp. 134–141, 2005.
- M. P. Santini, L. Tsao, L. Monassier et al., “Enhancing repair of the mammalian heart,” Circulation Research, vol. 100, no. 12, pp. 1732–1740, 2007.
- F. Tacke, D. Alvarez, T. J. Kaplan et al., “Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 185–194, 2007.
- L. M. Carlin, E. G. Stamatiades, C. Auffray et al., “Nr4a1-dependent Ly6Clow monocytes monitor endothelial cells and orchestrate their disposal,” Cell, vol. 153, no. 2, pp. 362–375, 2013.
- N. V. Serbina and E. G. Pamer, “Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2,” Nature Immunology, vol. 7, no. 3, pp. 311–317, 2006.
- S. Hayashidani, H. Tsutsui, M. Ikeuchi et al., “Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 285, no. 3, pp. H1229–H1235, 2003.
- A. Ducharme, S. Frantz, M. Aikawa et al., “Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction,” Journal of Clinical Investigation, vol. 106, no. 1, pp. 55–62, 2000.
- K. T. Weber, “Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation,” Circulation, vol. 96, no. 11, pp. 4065–4082, 1997.
- W. Iraqi, P. Rossignol, M. Angioi et al., “Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study,” Circulation, vol. 119, no. 18, pp. 2471–2479, 2009.
- R. Eschalier, M. Fertin, R. Fay et al., “Extracellular matrix turnover biomarkers predict long-term left ventricular remodeling after myocardial infarction insights from the reve-2 study,” Circulation: Heart Failure, vol. 6, no. 6, pp. 1199–1205, 2013.
- J. G. Simmons, J. B. Pucilowska, T. O. Keku, and P. K. Lund, “IGF-I and TGF-β1 have distinct effects on phenotype and proliferation of intestinal fibroblasts,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 283, no. 3, pp. G809–G818, 2002.
- C. F. Hung, M. G. Rohani, S.-S. Lee, P. Chen, and L. M. Schnapp, “Role of IGF-1 pathway in lung fibroblast activation,” Respiratory Research, vol. 14, no. 1, article 102, 2013.
- M. Nahrendorf, F. K. Swirski, E. Aikawa et al., “The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions,” The Journal of Experimental Medicine, vol. 204, no. 12, pp. 3037–3047, 2007.
- F. L. Chen, Z. H. Yang, Y. Liu et al., “Berberine inhibits the expression of TNFα, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARγ pathway,” Endocrine, vol. 33, no. 3, pp. 331–337, 2008.
- J. Tonkin, L. Temmerman, R. D. Sampson et al., “Monocyte/macrophage-derived IGF-1 orchestrates murine skeletal muscle regeneration and modulates autocrine polarization,” Molecular Therapy, vol. 23, no. 7, pp. 1189–1200, 2015.
- T. Heidt, G. Courties, P. Dutta et al., “Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction,” Circulation Research, vol. 115, no. 2, pp. 284–295, 2014.
- S. Epelman, K. J. Lavine, and G. J. Randolph, “Origin and functions of tissue macrophages,” Immunity, vol. 41, no. 1, pp. 21–35, 2014.
- A. R. Pinto, J. W. Godwin, and N. A. Rosenthal, “Macrophages in cardiac homeostasis, injury responses and progenitor cell mobilisation,” Stem Cell Research, vol. 13, no. 3, pp. 705–714, 2014.